S&P 500   2,514.38 (-99.51%)
DOW   21,269.38 (+1.56%)
QQQ   185.08 (+1.52%)
AAPL   242.25 (+0.56%)
FB   160.11 (+0.32%)
MSFT   154.05 (+1.28%)
GOOGL   1,111.40 (+0.84%)
AMZN   1,914.76 (+0.37%)
CGC   13.94 (+2.65%)
NVDA   252.18 (+3.75%)
BABA   189.64 (+1.11%)
MU   40.84 (+2.38%)
GE   7.15 (+1.42%)
TSLA   476.97 (-1.66%)
AMD   44.86 (+2.75%)
T   28.38 (+1.14%)
ACB   0.84 (+3.69%)
F   4.39 (-0.23%)
NFLX   366.23 (+0.59%)
BAC   20.40 (+3.14%)
GILD   74.81 (+3.17%)
DIS   95.55 (+0.66%)
S&P 500   2,514.38 (-99.51%)
DOW   21,269.38 (+1.56%)
QQQ   185.08 (+1.52%)
AAPL   242.25 (+0.56%)
FB   160.11 (+0.32%)
MSFT   154.05 (+1.28%)
GOOGL   1,111.40 (+0.84%)
AMZN   1,914.76 (+0.37%)
CGC   13.94 (+2.65%)
NVDA   252.18 (+3.75%)
BABA   189.64 (+1.11%)
MU   40.84 (+2.38%)
GE   7.15 (+1.42%)
TSLA   476.97 (-1.66%)
AMD   44.86 (+2.75%)
T   28.38 (+1.14%)
ACB   0.84 (+3.69%)
F   4.39 (-0.23%)
NFLX   366.23 (+0.59%)
BAC   20.40 (+3.14%)
GILD   74.81 (+3.17%)
DIS   95.55 (+0.66%)
S&P 500   2,514.38 (-99.51%)
DOW   21,269.38 (+1.56%)
QQQ   185.08 (+1.52%)
AAPL   242.25 (+0.56%)
FB   160.11 (+0.32%)
MSFT   154.05 (+1.28%)
GOOGL   1,111.40 (+0.84%)
AMZN   1,914.76 (+0.37%)
CGC   13.94 (+2.65%)
NVDA   252.18 (+3.75%)
BABA   189.64 (+1.11%)
MU   40.84 (+2.38%)
GE   7.15 (+1.42%)
TSLA   476.97 (-1.66%)
AMD   44.86 (+2.75%)
T   28.38 (+1.14%)
ACB   0.84 (+3.69%)
F   4.39 (-0.23%)
NFLX   366.23 (+0.59%)
BAC   20.40 (+3.14%)
GILD   74.81 (+3.17%)
DIS   95.55 (+0.66%)
S&P 500   2,514.38 (-99.51%)
DOW   21,269.38 (+1.56%)
QQQ   185.08 (+1.52%)
AAPL   242.25 (+0.56%)
FB   160.11 (+0.32%)
MSFT   154.05 (+1.28%)
GOOGL   1,111.40 (+0.84%)
AMZN   1,914.76 (+0.37%)
CGC   13.94 (+2.65%)
NVDA   252.18 (+3.75%)
BABA   189.64 (+1.11%)
MU   40.84 (+2.38%)
GE   7.15 (+1.42%)
TSLA   476.97 (-1.66%)
AMD   44.86 (+2.75%)
T   28.38 (+1.14%)
ACB   0.84 (+3.69%)
F   4.39 (-0.23%)
NFLX   366.23 (+0.59%)
BAC   20.40 (+3.14%)
GILD   74.81 (+3.17%)
DIS   95.55 (+0.66%)
Log in

NASDAQ:ALDX - Aldeyra Therapeutics Stock Price, Forecast & News

$2.08
-0.04 (-1.89 %)
(As of 04/2/2020 11:44 AM ET)
Today's Range
$2.03
Now: $2.08
$2.18
50-Day Range
$1.62
MA: $3.53
$5.33
52-Week Range
$1.48
Now: $2.08
$9.11
Volume32,472 shs
Average Volume323,903 shs
Market Capitalization$61.69 million
P/E RatioN/A
Dividend YieldN/A
Beta1.86
Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. Aldeyra Therapeutics, Inc. has a collaborative research agreement with Janssen Research & Development, LLC for the development of novel immune-modulating drugs for systemic inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.
Read More
Aldeyra Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALDX
CUSIPN/A
Phone781-761-4904

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.72 per share

Profitability

Net Income$-60,830,000.00

Miscellaneous

EmployeesN/A
Market Cap$61.69 million
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive ALDX News and Ratings via Email

Sign-up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter.


Aldeyra Therapeutics (NASDAQ:ALDX) Frequently Asked Questions

How has Aldeyra Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Aldeyra Therapeutics' stock was trading at $2.79 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ALDX shares have decreased by 25.4% and is now trading at $2.08. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Aldeyra Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aldeyra Therapeutics.

When is Aldeyra Therapeutics' next earnings date?

Aldeyra Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Aldeyra Therapeutics.

How were Aldeyra Therapeutics' earnings last quarter?

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) released its quarterly earnings results on Thursday, March, 12th. The biotechnology company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.21. View Aldeyra Therapeutics' earnings history.

What price target have analysts set for ALDX?

2 analysts have issued 12-month price targets for Aldeyra Therapeutics' stock. Their forecasts range from $20.00 to $33.00. On average, they anticipate Aldeyra Therapeutics' stock price to reach $26.50 in the next year. This suggests a possible upside of 1,174.0% from the stock's current price. View analysts' price targets for Aldeyra Therapeutics.

Has Aldeyra Therapeutics been receiving favorable news coverage?

News coverage about ALDX stock has trended very negative on Thursday, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aldeyra Therapeutics earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutAldeyra Therapeutics.

Are investors shorting Aldeyra Therapeutics?

Aldeyra Therapeutics saw a drop in short interest during the month of March. As of March 13th, there was short interest totaling 396,500 shares, a drop of 9.2% from the February 27th total of 436,600 shares. Based on an average trading volume of 254,700 shares, the days-to-cover ratio is presently 1.6 days. Currently, 1.7% of the company's shares are short sold. View Aldeyra Therapeutics' Current Options Chain.

Who are some of Aldeyra Therapeutics' key competitors?

What other stocks do shareholders of Aldeyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aldeyra Therapeutics investors own include Amarin (AMRN), Micron Technology (MU), Sorrento Therapeutics (SRNE), AVEO Pharmaceuticals (AVEO), Inovio Pharmaceuticals (INO), TherapeuticsMD (TXMD), AbbVie (ABBV), Amicus Therapeutics (FOLD), Gilead Sciences (GILD) and Sangamo Therapeutics (SGMO).

Who are Aldeyra Therapeutics' key executives?

Aldeyra Therapeutics' management team includes the following people:
  • Dr. Todd C. Brady, Chief Exec. Officer, Pres and Director (Age 46)
  • Mr. Stephen J. Tulipano CPA, MBA, Chief Financial Officer and Treasurer (Age 59)
  • Dr. David J. Clark M.D., M.R.C.P., A.F.P.M., Chief Medical Officer (Age 53)
  • Ms. Mary Taylor M.P.H., Sr. VP of Regulatory Affairs (Age 59)

What is Aldeyra Therapeutics' stock symbol?

Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol "ALDX."

How do I buy shares of Aldeyra Therapeutics?

Shares of ALDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aldeyra Therapeutics' stock price today?

One share of ALDX stock can currently be purchased for approximately $2.08.

How big of a company is Aldeyra Therapeutics?

Aldeyra Therapeutics has a market capitalization of $61.69 million. The biotechnology company earns $-60,830,000.00 in net income (profit) each year or ($2.05) on an earnings per share basis.  View additional information about Aldeyra Therapeutics.

What is Aldeyra Therapeutics' official website?

The official website for Aldeyra Therapeutics is http://www.aldeyra.com/.

How can I contact Aldeyra Therapeutics?

Aldeyra Therapeutics' mailing address is 131 HARTWELL AVENUE SUITE 320, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-761-4904 or via email at [email protected]


MarketBeat Community Rating for Aldeyra Therapeutics (NASDAQ ALDX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  437 (Vote Outperform)
Underperform Votes:  360 (Vote Underperform)
Total Votes:  797
MarketBeat's community ratings are surveys of what our community members think about Aldeyra Therapeutics and other stocks. Vote "Outperform" if you believe ALDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel